

## Trijardy XR - (5mg/2.5mg/1 g,10mg/5mg/1g,12.5mg/5mg/1g,25mg/5mg/1)

<b>Generic Name</b>	Empagliflozin, Linagliptan and Metformin Hydrochloride	<b>Innovator</b>	Boehringer Ingelheim
<b>Dosage</b>	5mg/2.5mg/1 g,10mg/5mg/1g,12.5mg/5mg/1g,25mg/5mg/1	<b>Branded US Sales</b>	Less Than \$1000 mn
<b>Probable FTF</b>	Less Than 5	<b>Known Para IV Filers</b>	Less Than 5
<b>Other ANDA developers</b>	More Than 5	<b>Tentative Approvals</b>	Less Than 5
<b>Final Approvals</b>	None	<b>Generic Launches</b>	None
<b>Indication</b>	TRIJARDY XR is a combination of empagliflozin, linagliptin, and metformin hydrochloride (HCl) indicated as an adjunct to diet and exercise to improve glycemc control in adults with type 2 diabetes mellitus		
<b>Complexities</b>	Yes		

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.